Autism ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Autism ' Pipeline Review, H2 2012
Published on August 2012

Report Summary


Summary

Global Markets Direct's, 'Autism - Pipeline Review, H2 2012', provides an overview of the Autism therapeutic pipeline. This report
provides information on the therapeutic development for Autism, complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic development for Autism. 'Autism - Pipeline Review, H2
2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites,
SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Autism.
- A review of the Autism products under development by companies and universities/research institutes based on information derived
from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Autism pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development
progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Autism.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Autism therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Autism ' Pipeline Review, H2 2012 (From Slideshare) Page 1/8


Table of Content

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Autism Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Autism 10
Autism Therapeutics under Development by Companies 12
Autism Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Early Clinical Stage Products 18
Discovery and Pre-Clinical Stage Products 19
Autism Therapeutics ' Products under Development by Companies 20
Autism Therapeutics ' Products under Investigation by Universities/Institutes 21
Companies Involved in Autism Therapeutics Development 23
F. Hoffmann-La Roche Ltd. 23
Sigma-Tau S.p.A. 24
Shenzhen Beike Biotechnology Co., Ltd. 25
Seaside Therapeutics 26
Snowdon Inc. 27
Curemark, LLC 28
Cellceutix Pharmaceuticals, Inc. 29
Heptares Therapeutics Ltd. 30
Autism ' Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
CM-AT - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
arbaclofen - Drug Profile 38
R&D Progress 38



Celexa - Drug Profile 40
R&D Progress 40
Mecamylamine - Drug Profile 41
R&D Progress 41
N-Acetylcysteine - Drug Profile 42
R&D Progress 42
KM-391 - Drug Profile 43
R&D Progress 43
N-Acetylcysteine - Drug Profile 45
R&D Progress 45
Zyprexa - Drug Profile 47
R&D Progress 47
Bumentanide - Drug Profile 48
R&D Progress 48
Oxytocin - Drug Profile 49
R&D Progress 49
Bumetanide - Drug Profile 50
R&D Progress 50
R&D Progress 51
Risperidone + Celecoxib - Drug Profile 53
R&D Progress 54
Buspirone - Drug Profile 55
R&D Progress 55



Aripiprazole - Drug Profile 56
R&D Progress 56
Aripiprazole + D-Cycloserine - Drug Profile 57
R&D Progress 58
D-Cycloserine - Drug Profile 59
R&D Progress 59
Aripiprazole - Drug Profile 60
R&D Progress 60
R&D Progress 61
Risperidone - Drug Profile 62
R&D Progress 62
Program For Neurological Disorders - Drug Profile 64
R&D Progress 64
mGluR5 Modulator - Drug Profile 65
R&D Progress 65
Human Cord Blood Mononuclear Cells + Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile 66
R&D Progress 66
Memantine - Drug Profile 67
R&D Progress 67
Human Cord Blood Mononuclear Cells - Drug Profile 68
R&D Progress 68
STX110 - Drug Profile 69
R&D Progress 69



RG7314 - Drug Profile 70
R&D Progress 70
Autism Therapeutics ' Drug Profile Updates 71
Autism Therapeutics ' Discontinued Products 75
Autism Therapeutics - Dormant Products 76
Autism ' Product Development Milestones 79
Featured News & Press Releases 79
Aug 15, 2012: Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs 79
Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism 79
May 31, 2012: Study Reports New Treatment For Irritability In Autism 79
Mar 27, 2012: Seaside Therapeutics Obtains Key Patent For Autism Drug Candidate STX209 80
Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism 81
Jul 08, 2011: Seaside Presents Phase IIa Data On STX209 In Autism Spectrum Disorders At 42nd Autism Society National
Conference 82
Jun 21, 2011: Seaside Therapeutics Initiates Phase IIb Study Of STX209 In Autism Spectrum Disorders 82
Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism 83
Oct 27, 2010: Curemark Adds Two Autism Trial Sites In California 83
Sep 09, 2010: Seaside Reports Positive Data From Phase II Study Of STX209 In Autism Spectrum Disorders 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Tables

Number of Products Under Development for Autism, H2 2012 10
Products under Development for Autism ' Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 22
F. Hoffmann-La Roche Ltd., H2 2012 23
Sigma-Tau S.p.A., H2 2012 24
Shenzhen Beike Biotechnology Co., Ltd., H2 2012 25
Seaside Therapeutics, H2 2012 26
Snowdon Inc., H2 2012 27
Curemark, LLC, H2 2012 28



Cellceutix Pharmaceuticals, Inc., H2 2012 29
Heptares Therapeutics Ltd., H2 2012 30
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 36
Autism Therapeutics ' Drug Profile Updates 71
Autism Therapeutics ' Discontinued Products 75
Autism Therapeutics ' Dormant Products 76
Autism Therapeutics ' Dormant Products (Contd..1) 77
Autism Therapeutics ' Dormant Products (Contd..2) 78

List of Figures

Number of Products under Development for Autism, H2 2012 10
Products under Development for Autism ' Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Discovery and Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Route of Administration, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Molecule Type, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 36


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Autism ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Autism ' Pipeline Review, H2 2012